Endomedix, Inc. was founded in September 2005 as a Delaware Corporation +by John Abrahams and William Chen.  The Company’s laboratory was located at the Long Island High Technology Incubator in Stony Brook, Long Island.  The firm was focused on the development of biopolymer chemistry to produce solutions that would form hydrogel devices in situ for various indications for use. The business model was to development technology for license and commercialization.   Projects that were pursued included applications for arteriovenous malformation and cerebral aneurysm repair, ocular, wound healing and dura mater repair.  A license agreement was executed with Integra Life Sciences for current and future technology in exchange for a cash payment and other considerations.

In 2010, the license agreement with Integra Life Sciences was terminated, and all rights to Endomedix technology and intellectual property were recovered without further obligation.  The business model of the firm was changed to emphasize the development of final products, intellectual property development, and product regulatory approvals leading to commercialization.  In May 2010, the Company’s laboratory and office was relocated to the Enterprise Development Center at the New Jersey Institute of Technology in New Jersey in Newark, New Jersey.  Since then, Endomedix has completed the development of its current generation of technology, obtained 7 patents, and is proceeding to develop its first product, a surgical hemostat for use in brain surgery.